年内12只“翻倍基”涌现，港股创新药板块成核心推手

Core Insights - As of July 31, 12 public funds have achieved a net value growth rate exceeding 100% in 2023, primarily focusing on themes such as innovative drugs, biomedicine, and healthcare, closely linked to the strong performance of the Hong Kong innovative drug sector [1][3] Group 1: Fund Performance - The top-performing fund, Huatai-PB Hong Kong Advantage Selection A, boasts a net value growth rate of 143.24%, heavily invested in Hong Kong innovative drugs [3] - Other notable funds include Changcheng Pharmaceutical Industry Selection A and Bank of China Hong Kong Stock Connect Pharmaceutical A, with six products also exceeding a 100% growth rate [3] - Five index funds, including Huatai-PB National Index Hong Kong Stock Connect Innovative Drug ETF and Wanji Zhongzheng Hong Kong Stock Connect Innovative Drug ETF, have also made it to the "doubling fund" list [3] Group 2: Market Drivers - The strong performance of the Hong Kong innovative drug sector since the beginning of the year has been the main driver for the growth of related thematic funds [3] - Three key factors driving this trend include: 1. Increased collaboration demand due to multinational pharmaceutical companies facing "patent cliffs," aligning with the harvest period for Chinese innovative drug companies [3] 2. Many biotech companies are expected to reach a breakeven point within the next three to five years [3] 3. Comprehensive policy support from research to payment, injecting strong momentum into industry development [3]